Arch Therapeutics Stock

Arch Therapeutics Stocks 2024

Arch Therapeutics Stocks

3.07 M

Ticker

ARTH

ISIN

US03939W1099

WKN

A1W2JT

In 2024, Arch Therapeutics had 3.07 M outstanding stocks, a 0% change from the 3.07 M stocks in the previous year.

The Arch Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e3.07
2025e3.07
2024e3.07
20233.07
20221.2
20211.1
20200.94
20190.83
20180.76
20170.71
20160.61
20150.41
20140.34
20130.11
20120.31
20110.06

Arch Therapeutics shares outstanding

The number of shares was Arch Therapeutics in 2023 — This indicates how many shares 3.074 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Arch Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arch Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arch Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arch Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arch Therapeutics Aktienanalyse

What does Arch Therapeutics do?

Arch Therapeutics Inc. is a Massachusetts-based company specializing in the development of medical devices. The company was founded in 2006 and has expanded its activities to manufacturing innovative medical products that can be used in various surgical procedures. The business model of Arch Therapeutics is based on the development of medical devices that aim to enable faster recovery for patients. The company utilizes a patented technology platform called "AC5" for the manufacturing and marketing of devices for various medical applications. The company has various divisions specializing in different medical applications. One main focus is the development of devices for hemostasis (blood clotting) in surgery, which is currently in the testing phase. Arch Therapeutics aims to provide a better alternative to existing solutions such as surgical clips or sutures, which are often associated with undesirable side effects. Another focus of Arch Therapeutics is the manufacturing of devices for dermatology. The company has developed a technology that enables a new and unique process for the rapid healing of wounds. This process is especially relevant for the treatment of difficult-to-heal wounds and chronic wounds. The company also has a division for ophthalmic surgery, which has developed a patented device technology for the treatment of glaucoma-related issues. This technology is intended to be a better alternative to conventional treatment methods such as eye drops. Arch Therapeutics' portfolio includes a wide range of medical devices and solutions for various medical applications. These products are designed to enable better patient recovery and have been developed by a group of experts, ensuring high quality and effectiveness. The offered products also include dermatology products, adhesion barriers, surgical J-clips, as well as wound closure and hemostasis devices. Overall, Arch Therapeutics has a strong potential for growth and expansion in the medical device industry. The company has already obtained patents for its AC5 platform and developed a wide range of products for various medical applications. With a dedicated team of employees, the company has laid a strong foundation for its future and is expected to remain a leading provider of medical devices in the coming years. Arch Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Arch Therapeutics's Shares Outstanding

Arch Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Arch Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Arch Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Arch Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Arch Therapeutics stock

How many stocks are there of Arch Therapeutics?

The current number of stocks of Arch Therapeutics is 3.07 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Arch Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Arch Therapeutics evolved in recent years?

The number of shares of Arch Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Arch Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Arch Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Arch Therapeutics pay?

Over the past 12 months, Arch Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arch Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Arch Therapeutics?

The current dividend yield of Arch Therapeutics is .

When does Arch Therapeutics pay dividends?

Arch Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arch Therapeutics?

Arch Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Arch Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arch Therapeutics located?

Arch Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arch Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arch Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Arch Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Arch Therapeutics in the year 2023?

In the year 2023, Arch Therapeutics distributed 0 USD as dividends.

In which currency does Arch Therapeutics pay out the dividend?

The dividends of Arch Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Arch Therapeutics

Our stock analysis for Arch Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arch Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.